NRx Receives Initial Report of Patient Safety and Survival from Right to Try use of ZYESAMI® (aviptadil) during Omicron Surge
- Wednesday, January 26, 2022, 7:03
- Finance
- Add a comment
RADNOR, Pa., Jan. 26, 2022 /PRNewswire/ — NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage, biopharmaceutical company, has received a first safety report from a Southwestern hospital where physicians have administered ZYESAMI® (Aviptadil) to patients with COVID-19 respiratory failure….
About the Author
adminasapcorp has written 41292 stories on this site.